JPRN-UMIN000002551已完成未知
Prospective examination of clinical efficacy of alendronate which is administrated prophylactically in glucocorticoid-induced osteoporosis - HASEB(Hyogo Association of Secondary Endocrine and Bone metabolism)Study 3
Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine0 个研究点目标入组 40 人开始时间: 2009年9月27日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Woman who hopes for pregnancy 2)Patient who has serious hepatopathy, renal damage, and cardiac disease 3)Patient who has received administering medicine that influences bone metabolism Medicine made of patient protein assimilation steroid(Winstrol, Primobolan, and Miotoron, etc.), Calcitonin(Elcitonin, Calcitriol, and Salmotonin, etc.), Ipriflavone(osten), vitamin K2(Glakey), androgenic hormone (TESTINON etc.), and female hormone (PREMARIN etc.), Raloxifene(Evista). However, after taking the medicine is stopped for eight weeks, it is possible to register. Patient who has received administering bisphosphonate. However, after taking the bisphosphonate is stopped for six months, it is possible to register. 4)Patient who judged it is improper to participation of physician in charge in clinical trial.
研究者
相似试验
已完成
2 期
A clinical trial to study and compare the effect of aloe vera and turmeric in patients with oral lichen planus.CTRI/2019/08/020856Sarkate Priyadarshani Rustum30
已完成
不适用
A prospective study on clinical efficacy of anti-allergic medical therapy and nitric oxide levels in patients with allergic rhinitis.allergic rhinitisJPRN-UMIN000016536Hiroshima University Hospital110
进行中（未招募）
不适用
A Phase III Study of the Efficacy and Safety of Alzhemed™ as Add-on Therapy in Mild to Moderate Alzheimer's Disease Patients.EUCTR2004-003435-31-SEeurochem Inc.930
进行中（未招募）
不适用
A Phase III Study of the Efficacy and Safety of Alzhemed™ as Add-on Therapy in Mild to Moderate Alzheimer's Disease Patients.EUCTR2004-003435-31-BEeurochem Inc.930
进行中（未招募）
1 期
A Phase III Study of the Efficacy and Safety of Alzhemed™ as Add-on Therapy in Mild to Moderate Alzheimer's Disease Patients.Alzheimer’s Disease (AD) is an irreversible, progressive neuro-degenartive disorder, characterized by gradual cognitive deficits associated with abnormal behaviour, personality changes, and which ultimately leads to dementia.Cerebral amyloid angiopathy (CAA) has also been found to be particularly common in Alzheimer patients.MedDRA version: 8.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseEUCTR2004-003435-31-GBeurochem Inc.930